Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.43 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.40 |
| ▸ | MGLL | Q99685 | 3/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16771247 | 0.91 | SCN9A (0.50) | SCN9ASCN7ASCN5A | |
| SCHEMBL16759257 | 0.87 | SCN9A (0.51) | SCN9ASCN7ASCN5AGPR119 | |
| SCHEMBL16759359 | 0.85 | SCN7A (0.49) | SCN9ASCN7ASCN5ASTS | |
| SCHEMBL16771206 | 0.82 | SCN9A (0.53) | SCN9ASCN7ASCN5A | |
| Hydrochloric Acid SCHEMBL17061970 | 0.81 | SCN9A (0.52) | SCN9ASCN7ASCN5A | |
| SCHEMBL16759619 | 0.81 | SCN9A (0.44) | SCN9ASCN7ASCN5AGPR119 | |
| SCHEMBL16759693 | 0.81 | SCN9A (0.46) | SCN9ASCN7ASCN5AMGLL | |
| SCHEMBL16771091 | 0.81 | SCN9A (0.56) | SCN9ASCN7ASCN5A | |
| SCHEMBL16759627 | 0.81 | SCN9A (0.51) | SCN9ASCN7ASCN5A | |
| SCHEMBL21825501 | 0.81 | SCN9A (0.60) | SCN9ASCN7ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SCN9A 1605/4885SCN7A 1270/4885SCN5A 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.